Print
Email
Print Edition Stories
MHT's Jackie Noblett: VC funds run short in 2009
MHT's Galen Moore: Honoring innovation in New England
Breaking down the MIT $100K
The serial biotech entrepreneurs who co-founded the biotech Sirtris Pharmaceuticals, now part of GlaxSmithKline PLC have launched a venture capital firm, raising $50.7 million in a first close.
Sirtris CEO Christoph Westphal and co-founders Richard Aldrich and Michelle Dipp are named in a regulatory filing posted on the U.S. Securities and Exchange Commission’s website yesterday afternoon by Longwood Founders Fund LP, a new venture capital firm based in an office in Boston’s Financial District.
Dipp, recently named a Mass High Tech Woman to Watch awardee, declined to comment on the trio’s plans for investing the new fund, or say the amount it is targeting for a final close. She also would not say whether GlaxoSmithKline (NYSE: GSK) is participating in the new fund. After going public in 2007, Sirtris sold to GlaxoSmithKline for $720 million in 2008, where it remains as a subsidiary unit.
Westphal, Aldrich and Dipp have co-founded three other life sciences startups since they began working together in 2005: Concert Pharmaceuticals Inc., Magen BioSciences Inc. and Alnara Pharmaceuticals Inc.
Both Westphal and Dipp are still at GlaxoSmithKline. Aldrich is chairman of the board at Alnara.
Longwood Founders Fund does not appear to have published a website.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
